secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2022-11-01T23:59:59+00:00
Accession:  0001628280-22-027568
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive reports Q3 2022 revenue $11.5M, net loss $12.5M; licensing deals and AQST-109 progress
--------------------------------------------------------------------------------

- Total revenues $11.5M (down from $13.3M Q3 2021); net loss $12.5M ($0.23/share) vs $14.6M ($0.37) prior year.
- Cash $18.6M; reaffirms FY2022 revenue guidance $46-49M and adjusted EBITDA loss $37-43M.
- AQST-109 epinephrine film: positive EPIPHAST II data; FDA EoP2 meeting scheduled Q4 2022.
- Licensing deals: Pharmanovia (Libervant EU/UK/MENA) $3.5M upfront; Otter/Assertio (Sympazan) $9M upfront + $6M milestone; Haisco (Exservan China) $7M upfront.
- Appointed Dr. Kenneth Truitt as CMO; Timothy Morris to board; exploring out-licensing Libervant North America.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828022027568/0001628280-22-027568-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828022027568/aqst-20221101.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-027568

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer